Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

9.1%

4 terminated out of 44 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

27%

12 trials in Phase 3/4

Results Transparency

32%

9 of 28 completed with results

Key Signals

9 with results88% success

Data Visualizations

Phase Distribution

32Total
Not Applicable (10)
P 1 (5)
P 2 (5)
P 3 (3)
P 4 (9)

Trial Status

Completed28
Unknown7
Withdrawn4
Terminated4
Active Not Recruiting1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (44)

Showing 20 of 20 trials
NCT04171817Phase 4CompletedPrimary

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT05632315Phase 2Active Not Recruiting

PMT for MDRO Decolonization

NCT03637400Phase 2CompletedPrimary

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

NCT01209234Not ApplicableCompletedPrimary

Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance

NCT05529173Phase 4Completed

Povidone-Iodine for Nasal Decolonization

NCT02814916Phase 3CompletedPrimary

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02363166CompletedPrimary

Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy

NCT02945241Phase 1CompletedPrimary

Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

NCT00324922Phase 3Completed

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

NCT02660554Not ApplicableCompleted

Trial of MRSA Polymerase Chain Reaction for Pneumonia

NCT02684422CompletedPrimary

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

NCT01509339Phase 1Withdrawn

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

NCT01855048Phase 1Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers

NCT03446053Phase 1Completed

A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers

NCT01138462Not ApplicableCompletedPrimary

Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions

NCT01438515Not ApplicableCompletedPrimary

Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization

NCT01925066Phase 2Completed

Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

NCT03886623Not ApplicableCompletedPrimary

A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients

NCT02365493Phase 3TerminatedPrimary

Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection

NCT00856089Phase 4WithdrawnPrimary

Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization

Scroll to load more

Research Network

Activity Timeline